DBVT News and Press, DBV Technologies S.A. From 03/12/21

Monthly information regarding the total number of voting rights and total number of shares of the Company as of February 28, 2021 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE Euronext Paris ISIN ...

Shares of DBV Technologies (NASDAQ: DBVT) were trading higher on Friday following the company's release of its full-year 2020 earnings report. Much more important than its financial results, however, the company provided encouraging regulatory updates. As of 3:27 p.m. EST today, the...

DBV Technologies S.A. (DBVT) Q4 2020 Earnings Conference Call March 11, 2021 5:00 PM ET Company Participants Anne Pollak - Head of Investor Relations Daniel Tassé - Chief Executive Officer & Director Pascal Wotling - Chief Technical Operations Officer Pharis Mohideen - Chief Medical ...

DBV Technologies (DBVT): FY GAAP EPS of -$2.95 beats by $0.75.Revenue of $11.28M (-23.3% Y/Y) misses by $6.49M.Press Release For further details see: DBV Technologies EPS beats by $0.75, misses on revenue

Montrouge, France, March 11, 2021 DBV Technologies Reports Full-Year 2020 Financial Results and Recent Business Developments DBV Technologies S.A. (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today re...

Montrouge, France, March 5, 2021 DBV Technologies to Participate in the H.C. Wainwright Global Life Sciences Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced th...

Montrouge, France, March 3, 2021 DBV Technologies Announces Date Change for Reporting Full Year 2020 Financial Results DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced tha...

Montrouge, France, March 1, 2020 DBV Technologies to Report Full Year 2020 Financial Results on March 4, 2021 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that the Com...

Montrouge, France, February 24, 2021 DBV Technologies to Participate in Upcoming AAAAI 2021 Congress DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced upcoming participatio...

Montrouge, France, February 22, 2021 DBV Technologies Announces Appointment of Michele F. Robertson as Chief Legal Officer DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced...